Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

被引：35
|
作者：
Abbas, Atheir [2 ]
Roth, Bryan L. [1 ]
机构：
[1] Univ N Carolina, Lineberger Canc Ctr, Natl Inst Mental Hlth Psychoact Drug Screening Pr, Chapel Hill, NC 27516 USA
[2] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2008年 / 9卷 / 18期
关键词：
5-HT2A; antipsychotic; inverse agonist; Parkinson's Disease; pimavanserin; psychosis; schizophrenia;
D O I：
10.1517/14656560802532707
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: Pimavanserin tartrate is the first 5-HT2A inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia. Pimavanserin is also being evaluated as a possible anti-insomnia drug. Objective: To discuss the potential of pimavanserin to fill multiple therapeutic needs. Methods: The problems with currently approved antipsychotics and sleep agents are explored to highlight how pimavanserin might address some longstanding issues in the treatment of psychosis and insomnia. Results/conclusions: In Phase II clinical trials, pimavanserin seemed to be safe, well-tolerated and efficacious in treating L-dopa-induced psychosis without worsening motor symptoms. Pimavanserin also potentiated the therapeutic effects of low-dose risperidone, reduced haloperidol-induced akathisia, and increased slow-wave sleep in older individuals.
引用
收藏
页码：3251 / 3259
页数：9
相关论文
共 50 条
  • [21] Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs
    Cunningham, Michael J.
    Bock, Hailey A.
    Serrano, Inis C.
    Bechand, Benjamin
    Vidyadhara, D. J.
    Bonniwell, Emma M.
    Lankri, David
    Duggan, Priscilla
    Nazarova, Antonina L.
    Cao, Andrew B.
    Calkins, Maggie M.
    Khirsariya, Prashant
    Hwu, Christopher
    Katritch, Vsevolod
    Chandra, Sreeganga S.
    McCorvy, John D.
    Sames, Dalibor
    ACS CHEMICAL NEUROSCIENCE, 2023, 14 (01): : 119 - 135
  • [22] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day
    Meltzer, Herbert Y.
    Elkis, Helio
    Vanover, Kimberly
    Weiner, David M.
    van Kammen, Daniel P.
    Peters, Perry
    Hacksell, Uli
    SCHIZOPHRENIA RESEARCH, 2012, 141 (2-3) : 144 - 152
  • [23] 5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence
    Higgins, Guy A.
    Sellers, Edward M.
    5-HT INTERACTION WITH OTHER NEUROTRANSMITTERS: EXPERIMENTAL EVIDENCE AND THERAPEUTIC RELEVANCE, PT A, 2021, 259 : 229 - 263
  • [24] Pimavanserin, a 5-hydroxytryptamine 2A receptor inverse agonist, reverses prepulse inhibition deficits in the nucleus accumbens and ventral hippocampus
    Shi, Mengwen
    Tang, Jiaxin
    Yang, Chengmei
    Guo, Guanlong
    Ou, Huaxing
    Chen, Weihai
    NEUROPHARMACOLOGY, 2021, 201
  • [25] Inverse agonists of the 5-HT2A receptor reduce nicotine withdrawal signs in rats
    Malin, David
    Henceroth, Mallori
    Rao, Gadam Srinivas
    Campbell, Joseph
    Ma, Jian-Nong
    Tsai, Ping-Hsun
    Kishbaugh, Jordan C.
    Burstein, Ethan S.
    NEUROSCIENCE LETTERS, 2019, 713
  • [26] Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an α1 agonist
    Shilling, PD
    Melendez, G
    Priebe, K
    Richelson, E
    Feifel, D
    PSYCHOPHARMACOLOGY, 2004, 175 (03) : 353 - 359
  • [27] Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an α1 agonist
    P. D. Shilling
    G. Melendez
    K. Priebe
    E. Richelson
    D. Feifel
    Psychopharmacology, 2004, 175 : 353 - 359
  • [28] Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Gαi1- and neutral antagonism for Gαq/11-proteins in human brain cortex
    Muneta-Arrate, Itziar
    Diez-Alarcia, Rebeca
    Horrillo, Igor
    Meana, J. Javier
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 36 : 83 - 89
  • [29] A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model
    Vanover, Kimberly E.
    Betz, Adrienne J.
    Weber, Suzanne M.
    Bibbiani, Francesco
    Kielaite, Aiste
    Weiner, David M.
    Davis, Robert E.
    Chase, Thomas N.
    Salamone, John D.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2008, 90 (04) : 540 - 544
  • [30] Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment
    Hietala, J
    Kuoppamäki, M
    Majasuo, H
    Pälvimäki, EP
    Laakso, A
    Syvälahti, E
    PSYCHOPHARMACOLOGY, 2001, 157 (02) : 180 - 187
12345